Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADICAL-IO cemiplimab for medically inoperable stage I non-small cell lung cancer
2025-524305-32-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Planned start Jun 2026; status: authorised.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-524305-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524305-32-00.